Refine
Year of publication
Document Type
- Preprint (564)
- Article (326)
- Conference Proceeding (2)
- Working Paper (2)
Has Fulltext
- yes (894)
Is part of the Bibliography
- no (894)
Keywords
- Heavy Ion Experiments (18)
- Hadron-Hadron scattering (experiments) (11)
- Heavy-ion collision (6)
- LHC (5)
- Hadron-Hadron Scattering (4)
- Quark-Gluon Plasma (4)
- ALICE experiment (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- Beauty production (2)
- Charm physics (2)
- Disposition Effect (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Immunenzymtechniken (2)
- Immunoenzyme Techniques (2)
- Jets (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Retail Investor (2)
- Sensitivity and Specificity (2)
- Sensitivität und Spezifität (2)
- Serodiagnosis (2)
- Single electrons (2)
- Viruslast (2)
- pp collisions (2)
- ALICE (1)
- ALICE detector (1)
- Anti-nuclei (1)
- Antigene Virale/Immunologie (1)
- Antigens,Viral/immunology (1)
- Automatisation (1)
- Blutspenderscreening (1)
- Bronchiolitis (1)
- Centrality Class (1)
- Centrality Selection (1)
- Chlamydia-Infections/urine (1)
- Chlamydieninfektionen/Urin (1)
- Chronisch aktive/Diagnostik (1)
- Collective Flow (1)
- Cytomegalie (1)
- Cytomegalovirus Infection (1)
- DNA, Virale/Blut (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Enzyme Linked Immunosorbent Assay (ELISA) (1)
- Enzyme-linked Immunosorbent Assay (1)
- Fibre/foam sandwich radiator (1)
- Financial Market Cycles (1)
- Genamplifikation (1)
- Gene-Amplification (1)
- HBV (1)
- HBsAg (1)
- HIV-Infektionen (1)
- HSV type specific antibodies (1)
- HSV-typenspezifische Antikörper (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Heavy Ion Experiment (1)
- Heavy Quark Production (1)
- Heavy flavor production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Hepatitis (1)
- Hepatitis B (1)
- Hepatitis B Antibodies/serum (1)
- Hepatitis B Core-Antigene/Immunologie (1)
- Hepatitis B-Antikörper/Serum (1)
- Hepatitis B-Core-Antigens-immunology (1)
- Hepatitis C (1)
- Hepatitis C; DNA (1)
- Hepatitis G virus (1)
- Hepatitis G-Virus (1)
- Hepatitis, Chronic Active/diagnosis (1)
- Herpes Simplex Virus/isolation and purification . (1)
- Herpes simplex Virus/Isolierung und Anreicherung (1)
- Higher Moments of Return (1)
- HlV-Infections (1)
- Household Finance (1)
- IgM/Immunologie (1)
- IgM/immunology (1)
- Immunsuppression (1)
- Interferon alpha (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Komplementbindungsreaktion (KBR) (1)
- Mid-rapidity (1)
- Mikroneutralisationstest (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Neural network (1)
- Nonfermenter (1)
- Nukleinsäureamplifikationstest (NAT) (1)
- Oberflächenantigen-Mutante (1)
- Paramyxoviridae (1)
- Particle Correlations and Fluctuations (1)
- Plasmapools (1)
- Plasmapräparate (1)
- Polioviren (1)
- Polymerase Chain Reaction (1)
- Polymerase Kettenreaktion (PCR) (1)
- Polymerasekettenreaktion (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proton–proton (1)
- QCD (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- RAS-ID-Gramneg (1)
- RNA, Virale/ Blut (1)
- Rapidity Range (1)
- ReagentKits, -Diagnostic (1)
- Reagenzkits, Diagnostische (1)
- Realization Utility (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Screening-ELISA (1)
- Selling Behavior (1)
- Serodiagnose (1)
- Serodiagnostik (1)
- Speculation (1)
- Systematic Uncertainty (1)
- TR (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transplantation/Immunologie (1)
- Transplantation/immunology (1)
- Trigger (1)
- Urethra/Mikrobiologie (1)
- Urethra/microbiology (1)
- Variation (Genetics) (1)
- Variation (Genetik) (1)
- Vector Boson Production (1)
- Viral Load (1)
- Viral Matrix Proteins (1)
- Viral/blood (1)
- Viral/blood; RNA (1)
- Virale Matrixproteine (1)
- Viremia-diagnosis (1)
- Virusisolierung (1)
- Virussicherheit (1)
- Western blot (1)
- Xenon-based gas mixture (1)
- anti-HBc (1)
- automation (1)
- blood donor screening (1)
- bronchiolitis (1)
- complement fixation assay (CF) (1)
- dE/dx (1)
- diagnostic window (1)
- diagnostisches Fenster (1)
- enzyme linked immunosorbent assay (ELISA) (1)
- harnwegspathogene Enterobacteriacae (1)
- heavy ion experiments (1)
- immunosuppression (1)
- microneutralization assay (1)
- non-fermenter (1)
- nucleic acid amplification test(NAT) (1)
- paramyxoviridae. (1)
- plasma pools and products (1)
- poliovirus (1)
- polymerase chain reaction (PCR) (1)
- quark gluon plasma (1)
- screening ELISA (1)
- spectra (1)
- surface antigen mutant (1)
- uropathogenic enterobacteriacae (1)
- viral contamination (1)
- viral load (1)
- virus isolation (1)
Institute
- Physik (877)
- Frankfurt Institute for Advanced Studies (FIAS) (809)
- Informatik (775)
- Medizin (15)
- Informatik und Mathematik (3)
- Center for Financial Studies (CFS) (2)
- Hochschulrechenzentrum (2)
- House of Finance (HoF) (2)
- Sustainable Architecture for Finance in Europe (SAFE) (2)
- Wirtschaftswissenschaften (2)
An excess of J/ψ yield at very low transverse momentum (pT<0.3 GeV/c), originating from coherent photoproduction, is observed in peripheral and semicentral hadronic Pb−Pb collisions at a center-of-mass energy per nucleon pair of sNN−−−√=5.02 TeV. The measurement is performed with the ALICE detector via the dimuon decay channel at forward rapidity (2.5<y<4). The nuclear modification factor at very low pT and the coherent photoproduction cross section are measured as a function of centrality down to the 10% most central collisions. These results extend the previous study at sNN−−−√=2.76 TeV, confirming the clear excess over hadronic production in the pT range 0−0.3 GeV/c and the centrality range 70−90%, and establishing an excess with a significance greater than 5σ also in the 50−70% and 30−50% centrality ranges. The results are compared with earlier measurements at sNN−−−√=2.76 TeV and with different theoretical predictions aiming at describing how coherent photoproduction occurs in hadronic interactions with nuclear overlap.
Measurement of anti-3He nuclei absorption in matter and impact on their propagation in the Galaxy
(2022)
In our Galaxy, light antinuclei composed of antiprotons and antineutrons can be produced through high-energy cosmic-ray collisions with the interstellar medium or could also originate from the annihilation of dark-matter particles that have not yet been discovered. On Earth, the only way to produce and study antinuclei with high precision is to create them at high-energy particle accelerators. Although the properties of elementary antiparticles have been studied in detail, the knowledge of the interaction of light antinuclei with matter is limited. We determine the disappearance probability of 3He when it encounters matter particles and annihilates or disintegrates within the ALICE detector at the Large Hadron Collider. We extract the inelastic interaction cross section, which is then used as an input to the calculations of the transparency of our Galaxy to the propagation of 3He stemming from dark-matter annihilation and cosmic-ray interactions within the interstellar medium. For a specifc dark-matter profle, we estimate a transparency of about 50%, whereas it varies with increasing 3He momentum from 25% to 90% for cosmic-ray sources. The results indicate that 3He nuclei can travel long distances in the Galaxy, and can be used to study cosmic-ray interactions and dark-matter annihilation.
Understanding the production mechanism of light (anti)nuclei is one of the key challenges of nuclear physics and has important consequences for astrophysics, since it provides an input for indirect dark-matter searches in space. In this paper, the latest results about the production of light (anti)nuclei in pp collisions at s√=13 TeV are presented, focusing on the comparison with the predictions of coalescence and thermal models. For the first time, the coalescence parameters B2 for deuterons and B3 for helions are compared with parameter-free theoretical predictions that are directly constrained by the femtoscopic measurement of the source radius in the same event class. A fair description of the data with a Gaussian wave function is observed for both deuteron and helion, supporting the coalescence mechanism for the production of light (anti)nuclei in pp collisions. This method paves the way for future investigations of the internal structure of more complex nuclear clusters, including the hypertriton.
W±-boson production in p–Pb collisions at √sNN = 8.16 TeV and Pb–Pb collisions at √sNN = 5.02 TeV
(2023)
The production of the W± bosons measured in p−Pb collisions at a centre-of-mass energy per nucleon−nucleon collision sNN−−−−√=8.16 TeV and Pb−Pb collisions at √sNN=5.02 TeV with ALICE at the LHC is presented. The W± bosons are measured via their muonic decay channel, with the muon reconstructed in the pseudorapidity region −4<ημlab<−2.5 with transverse momentum pμT>10 GeV/c. While in Pb−Pb collisions the measurements are performed in the forward (2.5<yμcms<4) rapidity region, in p−Pb collisions, where the centre-of-mass frame is boosted with respect to the laboratory frame, the measurements are performed in the backward (−4.46<yμcms<−2.96) and forward (2.03<yμcms<3.53) rapidity regions. The W− and W+ production cross sections, lepton-charge asymmetry, and nuclear modification factors are evaluated as a function of the muon rapidity. In order to study the production as a function of the p−Pb collision centrality, the production cross sections of the W− and W+ bosons are combined and normalised to the average number of binary nucleon−nucleon collision ⟨Ncoll⟩. In Pb−Pb collisions, the same measurements are presented as a function of the collision centrality. Study of the binary scaling of the W±-boson cross sections in p−Pb and Pb−Pb collisions is also reported. The results are compared with perturbative QCD (pQCD) calculations, with and without nuclear modifications of the Parton Distribution Functions (PDFs), as well as with available data at the LHC. Significant deviations from the theory expectations are found in the two collision systems, indicating that the measurements can provide additional constraints for the determination of nuclear PDF (nPDFs) and in particular of the light-quark distributions.
In our Galaxy, light antinuclei composed of antiprotons and antineutrons can be produced through high-energy cosmic-ray collisions with the interstellar medium or could also originate from the annihilation of dark-matter particles that have not yet been discovered. On Earth, the only way to produce and study antinuclei with high precision is to create them at high-energy particle accelerators. Although the properties of elementary antiparticles have been studied in detail, the knowledge of the interaction of light antinuclei with matter is limited. We determine the disappearance probability of 3He¯¯¯¯¯¯ when it encounters matter particles and annihilates or disintegrates within the ALICE detector at the Large Hadron Collider. We extract the inelastic interaction cross section, which is then used as input to calculations of the transparency of our Galaxy to the propagation of 3He¯¯¯¯¯¯ stemming from dark-matter annihilation and cosmic-ray interactions within the interstellar medium. For a specific dark-matter profile, we estimate a transparency of about 50%, whereas it varies with increasing 3He¯¯¯¯¯¯ momentum from 25% to 90% for cosmic-ray sources. The results indicate that 3He¯¯¯¯¯¯ nuclei can travel long distances in the Galaxy, and can be used to study cosmic-ray interactions and dark-matter annihilation.
Antimatter particles such as positrons and antiprotons abound in the cosmos. Much less common are light antinuclei, composed of antiprotons and antineutrons, which can be produced in our galaxy via high-energy cosmic-ray collisions with the interstellar medium or could also originate from the annihilation of the still undiscovered dark-matter particles. On Earth, the only way to produce and study antinuclei with high precision is to create them at high-energy particle accelerators like the Large Hadron Collider (LHC). Though the properties of elementary antiparticles have been studied in detail, knowledge of the interaction of light antinuclei with matter is rather limited. This work focuses on the determination of the disappearance probability of \ahe\ when it encounters matter particles and annihilates or disintegrates. The material of the ALICE detector at the LHC serves as a target to extract the inelastic cross section for \ahe\ in the momentum range of 1.17≤p<10 GeV/c. This inelastic cross section is measured for the first time and is used as an essential input to calculations of the transparency of our galaxy to the propagation of 3He¯¯¯¯¯¯ stemming from dark-matter decays and cosmic-ray interactions within the interstellar medium. A transparency of about 50% is estimated using the GALPROP program for a specific dark-matter profile and a standard set of propagation parameters. For cosmic-ray sources, the obtained transparency with the same propagation scheme varies with increasing 3He¯¯¯¯¯¯ momentum from 25% to 90%. The absolute uncertainties associated to the 3He¯¯¯¯¯¯ inelastic cross section measurements are of the order of 10%−15%. The reported results indicate that 3He¯¯¯¯¯¯ nuclei can travel long distances in the galaxy, and can be used to study cosmic-ray interactions and dark-matter decays.
The ALICE Collaboration reports the first fully-corrected measurements of the N-subjettiness observable for track-based jets in heavy-ion collisions. This study is performed using data recorded in pp and Pb−Pb collisions at centre-of-mass energies of √s=7 TeV and √sNN=2.76\,TeV, respectively. In particular the ratio of 2-subjettiness to 1-subjettiness, τ2/τ1, which is sensitive to the rate of two-pronged jet substructure, is presented. Energy loss of jets traversing the strongly interacting medium in heavy-ion collisions is expected to change the rate of two-pronged substructure relative to vacuum. The results are presented for jets with a resolution parameter of R=0.4 and charged jet transverse momentum of 40≤pT,jet≤60 GeV/c, which constitute a larger jet resolution and lower jet transverse momentum interval than previous measurements in heavy-ion collisions. This has been achieved by utilising a semi-inclusive hadron-jet coincidence technique to suppress the larger jet combinatorial background in this kinematic region. No significant modification of the τ2/τ1 observable for track-based jets in Pb--Pb collisions is observed relative to vacuum PYTHIA6 and PYTHIA8 references at the same collision energy. The measurements of τ2/τ1, together with the splitting aperture angle ΔR, are also performed in pp collisions at √s=7 TeV for inclusive jets. These results are compared with PYTHIA calculations at √s=7 TeV, in order to validate the model as a vacuum reference for the Pb−Pb centre-of-mass energy. The PYTHIA references for τ2/τ1 are shifted to larger values compared to the measurement in pp collisions. This hints at a reduction in the rate of two-pronged jets in Pb--Pb collisions compared to pp collisions.
The pT-differential production cross sections of prompt and non-prompt (produced in beauty-hadron decays) D mesons were measured by the ALICE experiment at midrapidity (|y|<0.5) in proton--proton collisions at s√=5.02 TeV. The data sample used in the analysis corresponds to an integrated luminosity of (19.3±0.4) nb−1. D mesons were reconstructed from their decays D0→K−π+, D+→K−π+π+, and D+s→ϕπ+→K−K+π+ and their charge conjugates. Compared to previous measurements in the same rapidity region, the cross sections of prompt D+ and D+s mesons have an extended pT coverage and total uncertainties reduced by a factor ranging from 1.05 to 1.6, depending on pT, allowing for a more precise determination of their pT-integrated cross sections. The results are well described by perturbative QCD calculations. The fragmentation fraction of heavy quarks to strange mesons divided by the one to non-strange mesons, fs/(fu+fd), is compatible for charm and beauty quarks and with previous measurements at different centre-of-mass energies and collision systems. The bb¯¯¯ production cross section per rapidity unit at midrapidity, estimated from non-prompt D-meson measurements, is dσbb¯¯¯/dy||y|<0.5=34.5±2.4(stat.)+4.7−2.9(tot.syst.) μb. It is compatible with previous measurements at the same centre-of-mass energy and with the cross section predicted by perturbative QCD calculations.
The pT-differential production cross sections of prompt and non-prompt (produced in beauty-hadron decays) D mesons were measured by the ALICE experiment at midrapidity (|y|<0.5) in proton--proton collisions at s√=5.02 TeV. The data sample used in the analysis corresponds to an integrated luminosity of (19.3±0.4) nb−1. D mesons were reconstructed from their decays D0→K−π+, D+→K−π+π+, and D+s→ϕπ+→K−K+π+ and their charge conjugates. Compared to previous measurements in the same rapidity region, the cross sections of prompt D+ and D+s mesons have an extended pT coverage and total uncertainties reduced by a factor ranging from 1.05 to 1.6, depending on pT, allowing for a more precise determination of their pT-integrated cross sections. The results are well described by perturbative QCD calculations. The fragmentation fraction of heavy quarks to strange mesons divided by the one to non-strange mesons, fs/(fu+fd), is compatible for charm and beauty quarks and with previous measurements at different centre-of-mass energies and collision systems. The bb¯¯¯ production cross section per rapidity unit at midrapidity, estimated from non-prompt D-meson measurements, is dσbb¯¯¯/dy||y|<0.5=34.5±2.4(stat.)+4.7−2.9(tot.syst.) μb. It is compatible with previous measurements at the same centre-of-mass energy and with the cross section predicted by perturbative QCD calculations.
Inclusive ψ(2S) production is measured in p-Pb collisions at the centre-of-mass energy per nucleon-nucleon pair sNN−−−√=8.16 TeV, using the ALICE detector at the CERN LHC. The production of ψ(2S) is studied at forward (2.03<ycms<3.53) and backward (−4.46<ycms<−2.96) centre-of-mass rapidity and for transverse momentum pT < 12 GeV/c via the decay to muon pairs. In this paper, we report the integrated as well as the ycms- and pT-differential inclusive production cross sections. Nuclear effects on ψ(2S) production are studied via the determination of the nuclear modification factor that shows a strong suppression at both forward and backward centre-of-mass rapidities. Comparisons with corresponding results for inclusive J/ψ show a similar suppression for the two states at forward rapidity (p-going direction), but a stronger suppression for ψ(2S) at backward rapidity (Pb-going direction). As a function of pT, no clear dependence of the nuclear modification factor is found. The relative size of nuclear effects on ψ(2S) production compared to J/ψ is also studied via the double ratio of production cross sections [σψ(2S)/σJ/ψ]pPb/[σψ(2S)/σJ/ψ]pp between p-Pb and pp collisions. The results are compared with theoretical models that include various effects related to the initial and final state of the collision system and also with previous measurements at sNN−−−√ = 5.02 TeV.
J/ψ production as a function of charged-particle multiplicity in p–Pb collisions at √sNN = 8.16 TeV
(2020)
Inclusive J/ψ yields and average transverse momenta in p-Pb collisions at a center-of-mass energy per nucleon pair sNN−−−√ = 8.16 TeV are measured as a function of the charged-particle pseudorapidity density with ALICE. The J/ψ mesons are reconstructed at forward (2.03<ycms<3.53) and backward (−4.46<ycms<−2.96) center-of-mass rapidity in their dimuon decay channel while the charged-particle pseudorapidity density is measured around midrapidity. The J/ψ yields at forward and backward rapidity normalized to their respective average values increase with the normalized charged-particle pseudorapidity density, the former showing a weaker increase than the latter. The normalized average transverse momenta at forward and backward rapidity manifest a steady increase from low to high charged-particle pseudorapidity density with a saturation beyond the average value.
J/ψ production as a function of charged-particle multiplicity in p–Pb
collisions at √sNN = 8.16 TeV
(2021)
Inclusive J/ψ yields and average transverse momenta in p-Pb collisions at a center-of-mass energy per nucleon pair sNN−−−√ = 8.16 TeV are measured as a function of the charged-particle pseudorapidity density with ALICE. The J/ψ mesons are reconstructed at forward (2.03<ycms<3.53) and backward (−4.46<ycms<−2.96) center-of-mass rapidity in their dimuon decay channel while the charged-particle pseudorapidity density is measured around midrapidity. The J/ψ yields at forward and backward rapidity normalized to their respective average values increase with the normalized charged-particle pseudorapidity density, the former showing a weaker increase than the latter. The normalized average transverse momenta at forward and backward rapidity manifest a steady increase from low to high charged-particle pseudorapidity density with a saturation beyond the average value.
W±-boson production in p–Pb collisions at √sNN = 8.16 TeV and Pb–Pb collisions at √sNN = 5.02 TeV
(2023)
The production of the W± bosons measured in p–Pb collisions at a centreof-mass energy per nucleon–nucleon collision √sNN = 8.16 TeV and Pb–Pb collisions at √sNN = 5.02 TeV with ALICE at the LHC is presented. The W± bosons are measured via their muonic decay channel, with the muon reconstructed in the pseudorapidity region −4 < ηµ lab < −2.5 with transverse momentum p µ T > 10 GeV/c. While in Pb–Pb collisions the measurements are performed in the forward (2.5 < yµ cms < 4) rapidity region, in p–Pb collisions, where the centre-of-mass frame is boosted with respect to the laboratory frame, the measurements are performed in the backward (−4.46 < yµ cms < −2.96) and forward (2.03 < yµ cms < 3.53) rapidity regions. The W− and W+ production cross sections, leptoncharge asymmetry, and nuclear modification factors are evaluated as a function of the muon rapidity. In order to study the production as a function of the p–Pb collision centrality, the production cross sections of the W− and W+ bosons are combined and normalised to the average number of binary nucleon–nucleon collision hNcolli. In Pb–Pb collisions, the same measurements are presented as a function of the collision centrality. Study of the binary scaling of the W±-boson cross sections in p–Pb and Pb–Pb collisions is also reported. The results are compared with perturbative QCD calculations, with and without nuclear modifications of the Parton Distribution Functions (PDFs), as well as with available data at the LHC. Significant deviations from the theory expectations are found in the two collision systems, indicating that the measurements can provide additional constraints for the determination of nuclear PDFs and in particular of the light-quark distributions.
Coherent photoproduction of ρ⁰ vector mesons in ultra-peripheral Pb-Pb collisions at √sNN = 5.02 TeV
(2020)
Cross sections for the coherent photoproduction of ρ0 vector mesons in ultra-peripheral Pb-Pb collisions at sNN−−−√ = 5.02 TeV are reported. The measurements, which rely on the π+π− decay channel, are presented in three regions of rapidity covering the range |y| < 0.8. For each rapidity interval, cross sections are shown for different nuclear-breakup classes defined according to the presence of neutrons measured in the zero-degree calorimeters. The results are compared with predictions based on different models of nuclear shadowing. Finally, the observation of a coherently produced resonance-like structure with a mass around 1.7 GeV/c2 and a width of about 140 MeV/c2 is reported and compared with similar observations from other experiments.
In particle collider experiments, elementary particle interactions with large momentum transfer produce quarks and gluons (known as partons) whose evolution is governed by the strong force, as described by the theory of quantum chromodynamics (QCD). These partons subsequently emit further partons in a process that can be described as a parton shower which culminates in the formation of detectable hadrons. Studying the pattern of the parton shower is one of the key experimental tools for testing QCD. This pattern is expected to depend on the mass of the initiating parton, through a phenomenon known as the dead-cone effect, which predicts a suppression of the gluon spectrum emitted by a heavy quark of mass mQ and energy E, within a cone of angular size mQ/E around the emitter. Previously, a direct observation of the dead-cone effect in QCD had not been possible, owing to the challenge of reconstructing the cascading quarks and gluons from the experimentally accessible hadrons. We report the direct observation of the QCD dead cone by using new iterative declustering techniques to reconstruct the parton shower of charm quarks. This result confirms a fundamental feature of QCD. Furthermore, the measurement of a dead-cone angle constitutes a direct experimental observation of the non-zero mass of the charm quark, which is a fundamental constant in the standard model of particle physics.
At particle collider experiments, elementary particle interactions with large momentum transfer produce quarks and gluons (known as partons) whose evolution is governed by the strong force, as described by the theory of quantum chromodynamics (QCD). The vacuum is not transparent to the partons and induces gluon radiation and quark pair production in a process that can be described as a parton shower. Studying the pattern of the parton shower is one of the key experimental tools in understanding the properties of QCD. This pattern is expected to depend on the mass of the initiating parton, through a phenomenon known as the dead-cone effect, which predicts a suppression of the gluon spectrum emitted by a heavy quark of mass m and energy E, within a cone of angular size m/E around the emitter. A direct observation of the dead-cone effect in QCD has not been possible until now, due to the challenge of reconstructing the cascading quarks and gluons from the experimentally accessible bound hadronic states. We report the first direct observation of the QCD dead-cone by using new iterative declustering techniques to reconstruct the parton shower of charm quarks. This result confirms a fundamental feature of QCD, which is derived more generally from its origin as a gauge quantum field theory. Furthermore, the measurement of a dead-cone angle constitutes a direct experimental observation of the non-zero mass of the charm quark, which is a fundamental constant in the standard model of particle physics.
The disposition effect is implicitly assumed to be constant over time. However, drivers of the disposition effect (preferences and beliefs) are rather countercyclical. We use individual investor trading data covering several boom and bust periods (2001-2015). We show that the disposition effect is countercyclical, i.e. is higher in bust than in boom periods. Our findings are driven by individuals being 25% more likely to realize gains in bust than in boom periods. These changes in investors’ selling behavior can be linked to changes in investors’ risk aversion and in their beliefs across financial market cycles.
Using German and US brokerage data we find that investors are more likely to sell speculative stocks trading at a gain. Investors’ gain realizations are monotonically increasing in a stock’s speculativeness. This translates into a high disposition effect for speculative and a much lower disposition effect for non-speculative stocks. Our findings hold across asset classes (stocks, passive, and active funds) and explain cross-sectional differences in investor selling behavior which previous literature attributed primarily to investor demographics. Our results are robust to rank or attention effects and can be linked to realization utility and rolling mental account.
Neben dem Erregernachweis beruht die Labordiagnose der Cytomegalie auf der Bestimmung HCMV spezifischer IgG-, IgM- und IgAAntikörper. Von der Industrie werden jedes Jahr neue Antikörpertests basierend auf der ELISA-Technologie angeboten. In der vorliegenden Studie wurden ein neues Testverfahren (Freka CMV-M-ELISA, Fresenius, Bad Homburg) mit bereits seit mehreren Jahren etablierten und zugelassenen ELISAs (Enzygnost CMVIgM; Behringwerke, Marburg und CMV-ELA, Medac, Hamburg) verglichen. Zur Bestimmung der Sensitivität wurden Verlaufsproben von 15 Organtransplantierten mit einer aktiven HCMV-Infektion, welche in den meisten Fällen über ein positives Ergebnis in der HCMV-DNA-PCR und/oder Virusisolierung und/oder quantitative pp65-Antigenbestimmung bestätigt wurde, untersucht. Zur Ermittlung der Spezifität wurde ein Kollektiv von bekannten HCMV-IgM-negativen Serumproben sowie potentiell kreuzreaktive Seren mit Antikörpern gegen andere Herpesviren und Rheumafaktor- bzw. Antinuklear-Antikörper-positive Seren untersucht. Die höchste Sensitivität wurde für den Medac-ELA ermittelt. Der Freka CMV-M ELISA zeigte eine ähnliche Sensitivität und Spezifität wie der Enzygnost CMV-IgM. Relativ zum Erregernachweis über PCR, Virusisolierung und quantitative pp65-Antigenbestimmung dauerte es bei vielen Patienten bis zu mehreren Wochen, ehe eine humorale Immunantwort über die Bildung von spezifischem IgM nachweisbar war. Bei zwei Patienten waren trotz dem Vorliegen einer floriden Cytomegalie keine HCMV-IgM-Antikörper bis zum Ende des Beobachtungszeitraums nachweisbar. Die Ergebnisse unserer Studie zeigen, daß es relativ große Unterschiede in bezug auf die Sensitivität der verschiedenen ELISAs gibt.
Insgesamt 311 Stämme gramnegativer harnwegspathogener Enterobacteriaceen und Nonfermenter, davon 200 Isolate aus frischem Urin der täglichen Routine und 111 ausgewählte, bezüglich ihrer Identifikation problematische Keime aus der Stammsammlung des Zentrums der Hygiene, Frankfurt/Main, wurden mit den Systemen RAS-ID-Gramne9, und API 20 E bzw. NE, vergleichend getestet. Das RAS~ID-Gramne9-System benutzt 10 biochemische Reaktionen zur Identifizierung gramnegativer Bakterien sowie 10 Chemotherapeutika zur Resistenzbestimmung. Von den 200 Routinestämmen zeigten 196 (98%), von den 111 Stämmen aus der Stammsammlung 98 (88,3 %) Übereinstimmung. Die gute Übereinstimmung und die schnelle und einfache Handhabung läßt das RAS-ID-Gramne9-System für die Identifizierung harnwegs-pathogener Routinekeime als kostengünstige Alternative zu anderen aufwendigeren Identifizierungssystemen erscheinen.
Highly sensitive qualitative and quantitative automatednucleic acid amplification tests (NATs) that are commercially available for the detection of hepatitis B virus (HBV)infection have been developed only in the last few years.The potential indications for HBV NATs are: follow-up ofchronic hepatitis B, therapy and antiviral resistance monitoring, determination of infectivity and transmission risk,detection of occult (HBsAg-negative and HBV DNA-positive) infection and mutant virus which may escape serologic diagnosis, blood donor screening, and resolution ofunusual or discordant serologic constellations. Although NATs are now widely implemented in the routine diagnosis of clinical laboratories, there are several importantissues which need to be further investigated. Standardisation of NATs used for the monitoring of antiviral therapyand follow-up of chronic infection is still lacking, and theclinical significance of HBV DNA levels needs to be clarified. The influence of genetic variability in terms of genotype variation has been poorly investigated so far.Although there are highly sensitive automated NATs forblood donor screening available, their implementation is still subject to discussion and certain countries rejectedHBV DNA testing for blood donation for reasons of poor cost-effectiveness.
Infektionen mit dem Respiratory Syncytial Virus (RSV)sind weltweit die bedeutendsten Atemwegserkrankungenim Säuuglings- und Kindesalter. Die RS-Viren werdend urch Schmierinfektionen und Aerosole übertragen, der Mensch ist das einzige Erregerreservoir. Im Säuglings-und Kleinkindalter finden gehäuft RSV-Infektionen statt. Mit zwei Jahren sind bereits 95% der Kinder seropositiv. Maternale Antikörper gewährleisten im Säuuglingsalterkeinen ausreichenden Nestschutz. Es ist von keiner sicheren Immunität auszugehen, daher sind Reinfektionen die Regel. Der Haüfigkeitsgipfel der RSV-Infektionenliegt in den Winter- und Frühlingsmonaten. Frühgeborene, immundefiziente und immunsupprimierte Patienten können das Virus mehrere Wochen ausscheiden. RSV-Infektionen verursachen zumeist Bronchitis, Bronchiolitis oder Pneumonie. Die Methode der Wahl ist der Erregernachweis über eine Virusisolierung in der Zellkultur im akuten Erkrankungsfall. Benötigt wird Nasenspülwasser oder ein tiefer Rachenabstrich. Auf einen schnellen Transport unter gekühlten Bedingungen ist zu achten (48C). Die Antikörpernachweise (Serologie) sind die Methode der Wahl für die epidemiologischen Auswertungen und weniger für die Akutdiagnostik geeignet. Nachdem Infektionsschutzgesetz (IfSG) § 6 Abs. 3 sind dem Gesundheitsamt gehäuft auftretende RSV-Infektionen zu melden. Die Therapie erfolgt symptomatisch; in schweren Fällen kann Ribavirin als Aerosol eingesetzt werden. Eine passive Immunisierung mit humanen Antikörpern gegen RSV kann bei Kindern mit erhöhtem Infektionsrisiko i.v. verabreicht werden (RespiGam). Auch sind monoklonale Antikörper gegen RSV (Palivizumab) prophylaktisch wirksam.
Der Nachweis von Chlamydia trachomatis Genomsequenzen ist seit einigen Jahren mit Hilfe kommerzieller Testkits, welche auf dem Prinzip der Polymerase-Ketten-Reaktion (PCR) oder Ligase-Kettenreaktion (LCR) beruhen, möglich. Vor kurzem wurde ein neues Verfahren, die Transcription Mediated Amplification (TMA), etabliert. In der vorliegenden Studie wurden drei Nukleinsäure Amplifikations-Techniken, die PCR, die LCR und die TMA für den Nachweis von Chlamydia trachomatis aus Urinproben miteinander bezüglich Sensitivität und Spezifität verglichen und einem Enzym-Immuno-Assay (EIA) zum C. trachomatis-Antigen-Nachweis aus endozervikalen Abstrichen gegenübergestellt. PCR, LCR und TMA zeigten eine vergleichbare Sensitivität und Spezifität. Diskrepante Ergebnisse ergaben sich im Vergleich mit dem C. trachomatis-Antigen-Nachweis. In 22 Abstrichen war Chlamydien-Antigen nachzuweisen. Nur bei 12 bzw. 11 der untersuchten Prostituierten konnten bei positivem zervikalen Abstrich Chlamydia trachomatis Genomsequenzen im Urin nachgewiesen werden. Bei 5 bzw. 4 Frauen wurde bei negativem Abstrichbefund C. trachomatis DNA bzw. RNA im Urin gefunden. Um bei Frauen eine hohe diagnostische Sensitivität zu erreichen, .sollten Urin und endozervikale Abstriche untersucht werden, da C. trachomatis nicht immer in beiden Probematerialien nachweisbar ist.
Der Nachweis von IgM-Antikörpern gegen das Hepatitis B Virus (HBV) "core" Protein wird für die Labordiagnose der akuten Hepatitis B sowie zur Verlaufskontrolle der chronischen HBV-lnfeklion eingesetzt. In letzter Zeit wurden sensitivere Enzymimmunoassays (EIA) entwickelt, welche den Nachweis einer geringen anti-HBc-IgM-Aktivität im Serum (10 lU/ml) ermöglichen. Über eine quantitative Bestimmung von anti-HBc-lgM mit Hilfe dieser EIAs ist die Differenzierung einer akuten und chronischen Infektion bzw. einer HBV-Reaktivierung in über 90% der Fälle möglich. Neben dem Nachweis der viralen DNA stellt anti-HBc-IgM einen prognostischen Marker für den Verlauf und die Therapie der chronischen Hepatitis B dar. Allerdings wird die Korrelation zwischen anti-HBc-IgM und HBV-Replikation kontrovers diskutiert. Es empfiehlt sich deshalb, insbesondere zur Therapiekontrolle eine quantitative HBV-DNA- und HBsAg-Bestimmung sowie den qualitativen HBeAg-Nachweis in monatlichen Intervallen durchzuführen. Eine weitere Einsatzmöglichkeit der anti-HBc-IgM-Bestimmung ist die Abklärung ungewöhnlicher Befundkonstellationen wie zum Beispiel eine HBsAg-negative akute Hepatitis B oder isolierte anti-HBc-Seropositivität.
The genetic variability of hepatitis B virus (HBV) represents a challenge for the sensitivity of immunodiagnosis, especially for the detection of surface antigen (HBsAg). There are two types of variants of HBV. Naturally occurring variants are the results of random changes selected over years of population pressure. These variants include HBV genotypes and unusual sequences, which may be poorly detected by immunoassays. The selected variants are mutants that arise in individuals under medically (vaccine, hepatitis B immune globulin and antiviral therapy) or naturally (chronic hepatitis B) induced immune pressure. HBV S-gene mutants have been identified in successfully immunized people worldwide. Based on the assumption that current vaccines containing S protein do not cross-protect against S gene mutants, a mathematical model predicts the disappearance of wild-type HBV in areas with HBsAg endemicity and the emergence of S gene mutants in approximately 100 years as a consequence of universal HBV vaccination. Mutant viruses may escape detection by commercial HBsAg kits. There are several reports on HBsAg negative carriers (HBVDNA positive) of S gene mutants with immunosilent infection or ‘‘unusual’’ serologic constellations. Although S gene mutants have been found to be associated with a more severe clinical course of HBV infection and hepatocellular carcinoma, the clinical significance of the genetic variability of HBV genotypes and HBsAg mutants needs to be further investigated. Detection of HBsAg needs to be improved by the introduction of new HBsAg assays able to recognize S gene mutants described so far and with a lower detection threshold than current immunoassays in order to detect smallest amounts of HBsAg in low-level carriers. There is also a need for more complete epidemiological data on the prevalence of HBsAg mutants in Western Europe and assays for the (differential) screening of mutants need to be developed and evaluated.
Die quantitative Bestimmung der Hepatitis B Virus (HBV) DNA mit Hilfe der Hybridisierung wird neben der klassischen Serologie zur Verlaufskontrolle der chronischen Hepatitis B seil längerer Zeit eingesetzt. Dagegen sind erst seit kurzem molekularbiologische Verfahren zur Quantifizierung der „Virus-Last bei der HIV- und Hepatitis C Virus (HCV) Infektion in Form kommerzieller Testkits verfügbar . Die HI V-1 RNA Kopienzahl stellt neben der CD4*-Zellzahl den zuverlässigsten prognostischen Marker, mit einer vergleichbar hohen Aussagekraft wie onkologische Stadieneinteilungen, dar. Dennoch bedürfen die aktuellen Testkits einiger Verbesserungen. Mangelhafte Reproduzierbarkeit im unteren Meßbereich, fehlende Standardisierung sowie eine schlechte Sensitivität für Non-B HIV-1 Subtypen stellen neben den hohen Reagenzienkosten die wichtigsten Nachteile der meisten zur Zeit verfügbaren Testkits dar. Bei der Verlaufskontrolle der chronischen Hepatitis B nimmt die Quantifizierung der HBV-DNA über Hybridisierung oder PCR nur eine untergeordnete Rolle ein. Der qualitative HBV-DNA-Nachweis wird bevorzugt zur Überprüfung der Infektiosität oder zur Abklärung ungewöhnlicher Serokonstellationen eingesetzt. Nach neueren Erkenntnissen wird der Verlauf der HCV-Infektion nicht oder nur unwesentlich vom Ausmaß der Viruslast beeinflußt. Als prognostische Faktoren spielen vor allem Alter, Geschlecht und Alkoholkonsum eine wesentliche Rolle. Dagegen scheint die Erfolgsaussicht der antiviralen Therapie mit der vor Behandlungsbeginn gemessenen Kopienzahl zu korrelieren.
Für eine rasche Labordiagnose der Herpes simplex Virus (HSV) Infektion ist ein schneller Erregernachweis von entscheidender Bedeutung. In der vorliegenden Arbeit wird eine schnelle, modifizierte Virusisolierung über den Nachweis von Virusstrukturproteinen mit Hilfe typenspezifischer monoklonaler Antikörper innerhalb von 36 Stunden (IPF-HSV) beschrieben. Es wurden insgesamt 560 Proben aus der Routinediagnostik vergleichend mit der konventionellen Virusisolierung über einen cytopathischen Effekt (CPE) und anschließender Typisierung (ZK-IFT) in infizierten Vero-Zellen und humanen Vorhautfibroblasten (HFF) untersucht. Die Sensitivität des IPF-HSV für HSV-1, bezogen auf den ZK-IFT (Vero-Zellen), betrug 96,8%. Für HSV-2 wurde eine Sensitivität von 93,9% ermittelt. Die Spezifität des IPF-HSV
lag für beide Virustypen über 99% (HSV-1: 99,4%, HSV-2: 99,1%). Bezogen auf die konventionelle Virusisolierung im erweiterten Referenzstandard (Vero-Zellen und HFF) zeigte der IPF-HSV etwas geringere Werte für die Sensitivität (91,4% für HSV-1; 91,6% für HSV-2). Unter den im Referenzstandard negativen Proben fanden sich mittels IPF-HSV eine HSV-1- und drei HSV-2-positive Proben. Die Spezifität lag für beide HSV-Typen über 99% (99,8% für HSV-1, 99,4% für HSV-2). Bezogen auf den Referenzstandard ergab sich für den IPF-HSV ein positiv prädiktiver Wert von 97,0% (HSV-1) bzw. 91,7% (HSV-2); der negative prädiktive Wert des Tests lag jeweils bei 99,4%. Die Ergebnisse unserer Studie zeigen, daß der IPF-HSV eine sinnvolle Alternative zur konventionellen Virusisolierung darstellt, da der Erregernachweis bereits nach 36 Stunden möglich ist. Der Testaufbau ist unter Verwendung geeigneter mojioklonaler Antikörper und Zelltypen auch zur Schnelldiagnose respiratorischer Viruserkrankungen, der Zytomegalie, dem kongenitalen Rötelnsyndrom und ggf. Rotavirusinfektionen geeignet.
Trotz der Spenderauswahl, des serologischen Screenings der Blutspenden auf antiHIV-1, anti-HIV-2, anti-HCV und HBsAg, Inaktivierungs- und Eliminierungsverfahren bleibt ein Restrisiko für hämatogen übertragbare Viren bei Plasmapools und den daraus hergestellten Präparaten. Als zusätzliche Screeningmethode zur Erhöhung der Virussicherheit wird inzwischen die Testung der Einzelspende bzw. von Minipools auf HCV-RNA verlangt. In der vorliegenden Arbeit wurden 142 HBsAg, anti-HCV- und anti-HIV-11-2 negative Plasmapools, sowie Plasmapräparate (Immunglobulinpräparat und F IX Präparat), welche zum Teil aus für HGV-RNA PCR-positiven Ausgangspools hergestellt worden waren, mittels PCR auf das Vorhandensein von HGV-Nukleinsäure untersucht. Alle untersuchten Pools bzw. Plasmapräparate stammten von Spenden zwischen 1994 und 1996, also vor der Einführung der genannten Pflichttestung auf HCV-RNA. HGV-RNA wurde in 117 der 142 Plasmapools (82,4%) amplifiziert. Allerdings war HGV-RNA nur in einer (6,3%) von 16 IgG-Chargen aus für HGV-Nukleinsäure positiven Kryoüberständen nachweisbar. In 2 (6,5%) von 31 unselektierten Immunglobulinpräparaten war eine HGV- Kontamination vorhanden. Eine routinemäßige Anwendung der PCR ist zur Zeit aus technischen sowie Kosten-Nutzen-Überlegungen für HGV nicht zu empfehlen, solange die klinische Relevanz nicht gesichert ist. Die Ergebnisse unterstreichen die Wichtigkeit der im Herstellungsprozeß integrierten Viruseliminierungsverfahren, denn bei der vorliegenden Studie konnte nur in einem geringen Anteil der Endproduktchargen HGV-Nukleinsäure nachgewiesen werden.
Mit Hilfe eines Pipettierroboters (Tecan RSP 4072) wurde ein automatisierter Mikroneutralisationstest zum quantitativen Nachweis neutralisierender Antikörper gegen Polioviren etabliert. Es konnte gezeigt werden, daß die Methode sehr gut reproduzierbar ist und die Untersuchungen von großen Kollektiven in relativ kurzer Zeit mit einem Minimum an Arbeitsaufwand im Vergleich zur manuellen Testdurchführung erlaubt. Die Seroprävalenzen gegen Poliovirus Typ 7, 2 und 3 wurden anhand von Serumproben von 1243 Patienten während eines Beobachtungszeitraums von 30 Monaten (Januar 1990 bis Juni 1992) untersucht. Die Poliovirus-Seropositivitätsrate gegen alle drei Typen betrug ca. 80%. Die höchsten Seroprävalenzen wurden dabei in der Gruppe der älteren Patienten (>50 Jahre) beobachtet. Insgesamt wies ein relativ hoher Anteil (7,4%) der Probanden gegen keinen der drei Poliovirus-Typen neutralisierende Antikörper auf. Daher sollten Impfungen weiterhin empfohlen werden, insbesondere für Reisende in
Endemiegebiete.
Herpes simplex virus type 2 (HSV-2) is the main cause of herpes genitalis, a recurrent sexually transmitted disease. By the use of routine Serologie methods (complement fixation test, enzyme immunoassay), virus carriers are difficult to identify because of strong antibody cross reactions with antigens of HSV-1 which is ubiquitously spread throughout the population. We introduce a microtechnique Western blot system loaded with HSV-1 and HSV-2 type-specific and common antigens on separated nitrocellulose strips. By the simultaneous evaluation of Immunologie reactions with both strips, the occurrence of HSV-2 specific antibodies can be sensitively detected in serum specimens containing antibodies to HSV-1. A total of 158 serum specimens were analyzed and the results obtained by Western blot were compared to those of a screening ELISA and virus isolation performed with smears of herpes lesions.
An agreement of 97.9 % was assessed between Western blot and virus isolation to detect an HSV-1 and HSV-2 infection. Less specific serologic results were produced by the screening ELISA on HSV-2 antibodies which correlated in 85.4 % (41/48) with virus isolation and typing. Concerning HSV-2 antibody testing, Western blot and ELISA showed an overall agreement in 89.8 % of the sera investigated.
As shown by our data, the HSV type specific Western blot proved to be a specific, reproducible and standardized technique. It can be utilized for both sero-epidemiological surveys and determination of the HSV immune status.